ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CTSO vs PAVM // EV/EBITDA & P/E VALUATION

Cytosorbents Corporation (NASDAQ) VS. PAVmed Inc. (NASDAQ) • 15-METRIC TALLY: CTSO 5 — PAVM 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTSO VS. PAVM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CTSO PAVM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 71.50% -30.00% +101.50 CTSO /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -39.80% -60.00% +20.20 CTSO /operating-margins <GO>
Net Profit Margin -22.10% -60.00% +37.90 CTSO /net-margins <GO>
Revenue Growth (YoY) — -65.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 1/9 +2.00 CTSO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.9 26.5 +21.33 CTSO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $13.9M $15.8M -$1.9M PAVM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CTSO REV PAVM REV CTSO GROSS % PAVM GROSS % CTSO FCF PAVM FCF
FY 2025 $37.1M $71.0K 71.5% -50.0% -$12.5M -$5.2M
FY 2024 $35.6M $3.0M 69.9% -50.0% -$14.7M -$33.6M
FY 2023 $0 $2.5M — — -$21.7M -$52.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTSO // BETA —
PAVM // BETA —